Tamoxifen for breast cancer prevention

Summary:

Tamoxifen is of proven efficacy in the treatment of breast cancer. New data indicate that it might be able to reduce the occurrence of receptor positive breast cancer when taken as a preventative. However trade-offs for this reduction are an increased incidence of endometrial carcinomas and thrombo-embolic events. Therefore the use of tamoxifen as preventative ought to be restricted to clinical studies or a well defined high risk situation. Whether raloxifen is superior to tamoxifen remains to be shown.

Tamoxifen - raloxifen - breast cancer - prevention

References

• 1 Anderson M, Storm H H, Mouridsen H T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer.  J Natl Cancer Inst. 83 1013-1017 1991; 
• 2 De Muylder X, Neven P, De Somer Y, Van Belle Y, Vanderick G, De Muylder E. Endometrial lesions in patients undergoing tamoxifen therapy.  Int J Gynecol Obstet. 36 127-130 1990; 
• 3 Dilts P V, Hopkins M, Chang A, Cody R L. Rapid growth of leiomyoma in patients receiving tamoxifen.  Am J Obstet Gynecol. 166 167-168 1992; 
• 4 Fisher B, Constantino J P, Wickerham D L, Redmond C K, Kavanah M, Cronin W M, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.  J Nat Cancer Inst. 90 1371-1388 1998; 
• 5 Fornander T, Rutquist L E, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N. et al. . Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancer.  Lancet. I 117-120 1989; 
• 6 Hajjar L RK, Wooshin G H, Nolan S, Turner S, Raju U R. Intestinal and pelvic endometriosis presenting as a tumor and associated with tamoxifen therapy: report of a case.  Obstet Gynecol. 82 642-644 1993; 
• 7 Jordan V C, Morrow M. Tamoxifen, Raloxifene, and the prevention of breast cancer.  Endocr Rev. 20 253-278 1999; 
• 8 Kang J, Baxi L, Heller D. Tamoxifen-induced growth of leiomyomas.  J Reprod Med. 41 119-120 1996; 
• 9 Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen P J, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen.  Obstet Gynecol. 81 660-664 1993; 
• 10 Magriples U, Naftolin F, Schwartz P E, Carcangiu M L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.  J Clin Oncol. 11 485-490 1993; 
• 11 Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy V A, Viggers J, Davey J B. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.  Lancet. 352 (9122) 98-101 1998; 
• 12 Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.  Lancet. 352 (9122) 93-97 1998;